Astrazeneca Pharma India reports standalone net profit of Rs 0.79 crore in the September 2016 quarter
Up to 31 July 2017AstraZeneca Pharma India announced the Company has received on 01 December 2016 a notice to extend the date of distribution arrangements for Meronem up to 31 July 2017, during which time the parties shall continue to act in accordance with the terms and conditions of the Agreement. The extension is due to the delay in the divestment of AstraZeneca's global rights to Meronem.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)